Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
about
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Cost-effectiveness of BRCA1 an ...... tive recurrent ovarian cancer.
@en
Cost-effectiveness of BRCA1 an ...... tive recurrent ovarian cancer.
@nl
type
label
Cost-effectiveness of BRCA1 an ...... tive recurrent ovarian cancer.
@en
Cost-effectiveness of BRCA1 an ...... tive recurrent ovarian cancer.
@nl
prefLabel
Cost-effectiveness of BRCA1 an ...... tive recurrent ovarian cancer.
@en
Cost-effectiveness of BRCA1 an ...... tive recurrent ovarian cancer.
@nl
P2093
P1476
Cost-effectiveness of BRCA1 an ...... tive recurrent ovarian cancer.
@en
P2093
Bercedis L Peterson
Evan R Myers
Jason Cory Barnett
Jonathan A Ledermann
P304
P356
10.1097/IGC.0B013E31829527BD
P577
2013-06-01T00:00:00Z